Clearmind Medicine
CMND
5 hedge funds and large institutions have $5.45M invested in Clearmind Medicine in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
1% less capital invested
Capital invested by funds: $5.49M → $5.45M (-$38.8K)
2.28% less ownership
Funds ownership: 13.99% → 11.71% (-2.3%)
17% less funds holding
Funds holding: 6 → 5 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$70.9K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$16.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$54K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$52.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.29K |
CMND Hedge Fund Activity: Q1 2025 in Review
5 of the 7,477 institutional investors tracked by Wall St. Rank reported a position in Clearmind Medicine (CMND) for Q1 2025, worth a combined $5.45M — down 0.71% from $5.49M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CMND and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was AdvisorShares Investments, adding an estimated $70.9K. The largest seller was Virtu Financial, exiting entirely with an estimated $54K sold.
- 5 institutional investors held Clearmind Medicine (CMND) as of Q1 2025, down from 6 in Q4 2024.
- Funds reported $5.45M of Clearmind Medicine stock for Q1 2025, down 0.71% quarter-over-quarter.
- 1 fund opened new Clearmind Medicine positions in Q1 2025 and 2 closed out, a net change of -1 holder.
- The largest Clearmind Medicine buyer in Q1 2025 was AdvisorShares Investments, an estimated $70.9K added.
- The largest Clearmind Medicine seller in Q1 2025 was Virtu Financial, an estimated $54K sold.
Based on aggregated 13F filings for Q1 2025.